Innovative peptides against cancer and pathogenic bacteria, with advances in science, biopharmaceutical drug development, product market targeting, training , and communication.

INPACT aims at the pre-clinical development of innovative drugs and drug formulations against selected cancers (eg prostate cancer) and pathogenic bacteria (eg S. aureus). The INPACT consortium allies the expertise of both academic and industrial R&D part

  • Listing ID: 1985
  • Start date: 2/1/2015
  • End Date: 1/31/2019
  • Region: Canary Islands
  • Priority: Health & Wellness
  • Programme: MSCA-RISE-2014
  • Participants within MAC area: CENTRO ATLANTICO DEL MEDICAMENTO, SA: 45,000.00

Leave a Reply

You must be logged in to post a comment.